Point-of-Care Cell Manufacturing Committee

BioCanRx has established a Point-of-Care (POC) Cell Manufacturing Committee, made up of scientists, clinicians and guided by subject matter experts, to oversee the expansion and integration of our POC manufacturing sites into a functional network across Canada. The benefit of our POC network is to enable access to cutting-edge, cellular cancer immunotherapies to Canadians through clinical trials.

 

Members of the committee

 

Dr. Harry Atkins
Scientist, Cancer Therapeutics Program, Ottawa Hospital Research Institute
Attending Physician, Blood and Marrow Transplant Program, The Ottawa Hospital
Associate Professor, Clinical Hematology, University of Ottawa
Dr. John Bell
Scientific Director, BioCanRx
Senior Scientist, The Ottawa Hospital
Professor, uOttawa
Dr. Kevin Hay
Clinical Scientist and Hematologist, The Leukemia/Bone Marrow Transplant Program of BC, BC Cancer
Dr. Michael Jamieson
Director of Clinical Translation and Core Investigator, Clinical Epidemiology, Ottawa Hospital Research Institute
Dr. Natasha Kekre
Associate Scientist, Clinical Epidemiology Program, Ottawa Hospital Research Institute
Hematologist, Blood and Marrow Transplant Program, The Ottawa Hospital
Assistant Professor, University of Ottawa
Dr. Brad Nelson
Distinguished Scientist and Director, Deeley Research Centre
Scientific Co-director, Immunotherapy Program, BC Cancer
Dr. Christine Williams
Deputy Director, Ontario Institute for Cancer Research (OICR)
Dr. Armin Gerbitz
Staff Physician, Hans Messner Allogeneic Transplantation Program; Professor of Medicine, University of Toronto

 

BioCanRx Staff

 

 
Dr. Stéphanie Michaud, President and Chief Executive Officer Dr. Jennifer Quizi, Director, Biotherapeutics Manufacturing Operations Dr. Megan Mahoney, Director, Scientific Affairs and Training Programs